Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease
Susanna C. Larsson, Dipender Gill, Amy M. Mason, Tao Jiang, Magnus Bäck, Adam S. Butterworth, Stephen Burgess
Abstract
heart valve diseases lipoprotein(a) Mendelian randomization analysis stroke L ipoprotein(a) (Lp[a]) is a circulating lipoprotein with proatherogenic, proinflammatory, and possibly prothrombotic properties. Circulating Lp(a) levels are largely genetically determined, in particular, by the LPA gene. As such, genetic variants at the LPA locus can serve as instrumental variables for investigating the clinical effects of circulating Lp(a) levels. 3] Whether Lp(a) is causally related to thrombotic disease and cerebrovascular disease remains unclear. n this study, we used the UK Biobank cohort to perform an MR investigation into the causal effects of circulating Lp(a) levels on atherosclerotic, cerebrovascular, thrombotic, and valvular diseases. Because a recent MR study provided evidence of an inverse association of Lp(a) levels with Alzheimer disease,